Experiments revealed that one i.v. dose of mpJX administered with repeated doses of the anti-PD-1 antibody infected both primary tumors and metastases and had synergistic effects on the influx of NK cells, CD8+ T cells, and other immune cells and on tumor cell killing and suppression of tumor cell proliferation. Here, CD8A is linked to neoplasm.